Chen et al. Appendicitis associated increased risk incident SLE in population-based case-control study from Taiwan. HR 2.04 @RheumNow #ACR22 Abstr#1750 https://t.co/L9dTpMdHNP https://t.co/mEHeL6JnuE

• Association Between Appendicitis and the Risk of Systemic Lupus Erythematosus: …

#ACR2022 L07: Telitacicept - anti-BlyS and APRIL in SLE 335 pts P3 52 wk study TEL 160 mg SQ q7d vs PBO 83% SRI4 response in TEL vs 38% PBO (p<0.001) As early as w4, sustained to w52 Most common AEs: URIs, decr IgG/IgM, injxn site rxn, UTI @RheumNow #ACRBest https://t.co/UpEwEaonDO

A Novel Treatment Response Measurement Tool for Lupus Dr. Dao discusses abstract 2054 with Dr. Morand at the #ACR22 Convergence. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process. https://t.co/iqqyI953Vz https://t.co/taUjTHsrJ2

• https://bit.ly/3hGxCEv

Even young SLE patients are still at high risk of severe COVID: - in general pop, age is key factor - in SLE, risk is high across age groups (maybe due to both meds & disease) - vaccination makes a big diff but SLE pts still at high risk ABST1591 @CCalabreseDO #ACR22 @RheumNow https://t.co/ra1F79ITn3

Wu et al Phase 3 RCT of Telitacicept (targets BlyS and APRIL) in SLE. Primary endpoint met at week 52! SRI(4) 67% vs 33% or 83% vs 38% (P<0.001 for both) depending on how you want to slice it. @RheumNow #ACR22 Abstr#L07 https://t.co/nnKr4AU8Jk https://t.co/9BVF6OljFQ

• Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimula…

#ACR22 Abstr#2068 Data from John Hopkins showed leading cause of deaths (1985-2019) in #lupus were #SLE & Cardiovascular (both 23%), then cancer & infection.SLE deaths common in younger. African-American died younger vs White. Need to improve with therapies we now have @RheumNow https://t.co/4tDhr1Eodm

#ACR22 Abstr#2061 It's time to tight control newly diagnosed #lupus nephritis patients. In a cohort study which 16% developed advanced CKD, risk was reduced if remission achieved by 12 mths of diagnosis. =>1 flare & shorter time-on-therapy increased risk @RheumNow #ACRBest https://t.co/swYn2g4hqe

#SLE mortality in South Carolina Lupus Cohort Standardized mortality ratio (SMR) is higher in blacks Higher SLICC scores in blacks abst#2106 #ACR22 @rheumnow https://t.co/NAdNhUHsbc

New SLE Rx. Deucravitinib a TYK2i phase 2 RCT showed SRI4 endpoint. Subset of 3 mg bid was best vs 6 mg bid and 12 mg OD. Skin via CLASI-50 & other endpoints also positive. Awaiting phase III. Abst1117 #ACR22 @RheumNow https://t.co/fZI3AV5pML

Hidekawa et al. HCQ use assoc reduced severe infection in LUNA SLE registry, HR 0.26. ?due to better disease control rather than anti-infectious role, but HR 0.32 in multivariable model including SLEDAI. @RheumNow #ACR22 Abstr#2059 https://t.co/EgTJOAymoF https://t.co/gmchk9ZS5L

• Association of Hydroxychloroquine with the Incidence of Infectious Disease in S…

Figueroa Parra @AliDuarteMD et al. Multimorbidity in SLE. Higher at classification - due to non-SLE assoc. SLE-assoc drive increased accumulation over time but non-SLE assoc also increased @RheumNow #ACR22 Abstr#2091 https://t.co/6IyhovSNYA https://t.co/qmYfoqCTtz

• Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Com…

#ACR22 Abstr#2055 SRI-4 and BICLA: how do they converge and diverge? Analyses of 6 x Non-Renal #Lupus RCT showed discordance (12-30%).When discordant, SRI-4 classified more pts as responders vs BICLA. Concordance higher at 52 vs 24 wks. Vital to interpret both outcomes @RheumNow https://t.co/prSfTrv0E8

#ACR22 Abstr#1764 In addition to race, what social health aspect to consider when assessing #lupus epidemiology? A study identified urbanicity and area deprivation index were associated with SLE diagnosis. Could those living in the city = better access and diagnosis? @RheumNow https://t.co/PsNt8vQufs

Urine Proteomics in SLE with Dr. Michelle Petri Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria, being presented Saturday at #ACR22. https://t.co/rBDnbSqQCI https://t.co/WfERf1k5VB

• https://bit.ly/3UUdey4